Dendreon’s continued slump appears to have forced its hand: Bloomberg reported Monday that the drugmaker, known for its prostate cancer med Provenge, has asked JPMorgan Chase to help it find a buyer.
Dendreon’s financial forecasts have been dim: the company managed to narrow its losses during the second quarter, but said in August that it would not be able to hit its 2013 sales target, despite proof that potential patients were responding to its television ads.
